Navigation Links
Olivier BOHUON appointed Chief Executive Officer of Pierre Fabre SA
Date:9/1/2010

Olivier BOHUON appointed Chief Executive Officer of Pierre Fabre SA -- CASTRES, France, September 1, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Olivier BOHUON appointed Chief Executive Officer of Pierre Fabre SA

 

CASTRES, France, September 1, 2010 /PRNewswire/ -- During its first meeting, the Board of Directors of Pierre Fabre SA chaired by Mr. Pierre Fabre appointed Olivier BOHUON as the company's Chief Executive Officer.

Olivier BOHUON, 51, has until now been the executive vice-president of Abbott Corporation and president of its pharmaceutics division. In this capacity, he directed the group's entire pharmaceutical business (22 billion dollars turnover) from Chicago. He also became group president for Europe in 2003 and subsequently president of Abbott international.

Olivier BOHUON has also been appointed president of Pierre Fabre Medicament as of today.

About the Pierre Fabre group

The Pierre Fabre group, owned on a majority basis by a public utility Foundation, is France's second largest independent pharmaceutics laboratory and the leader in cosmetics products sold in pharmacies.

It employs a workforce of nearly 10,000 including 1,400 in research.

In 2009, the Pierre Fabre group achieved a turnover of 1.8 billion EUR and dedicated 28% of its medical turnover to research and development in three main therapeutic areas: oncology, central nervous system, dermatology and cardio-vascular/metabolism.

To find out more about Laboratoires Pierre Fabre : http://www.pierre-fabre.com


'/>"/>
SOURCE Groupe Pierre Fabre
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Olivier Bohuon Joins Pierre Fabre
2. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
3. Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
4. Robert Cantu Appointed Vice President of Pierpoint International
5. Timothy I. Still Appointed CEO at Accumetrics
6. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
7. Paul Keim Appointed to febits Scientific Advisory Board
8. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
9. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
10. FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
11. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... business in Hong Kong. , Nerium International is proud to introduce its Age-Defying ... Contour Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products ...
(Date:2/17/2017)... PUNE, India , February 17, 2017 /PRNewswire/ ... research report "Biomarkers Market by Product (Consumables, Service), ... Disorders), Application (Diagnostics Development, Drug Discovery and Development, ... MarketsandMarkets, the market is projected to reach USD ... in 2016, growing at a CAGR of 13.8% ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
(Date:1/18/2017)... ROCKVILLE, Md. , Jan. 18, 2017  In ... with respect to mergers and acquisitions (M&A), and Kalorama ... reasons for such acquisitions have been shifting. Generally, uncertainty ... and the U.S. has changed the acquisitions ... situation has resulted in companies buying partners outside of ...
Breaking Biology News(10 mins):